Goldman Sachs Group Inc. Initiates Coverage on ChemoCentryx (CCXI)
Analysts at Goldman Sachs Group Inc. started coverage on shares of ChemoCentryx (NASDAQ:CCXI) in a research report issued to clients and investors on Monday, TheFlyOnTheWall.com reports. The firm set a “neutral” rating and a $7.00 price target on the stock. Goldman Sachs Group Inc.’s price objective would indicate a potential upside of 15.70% from the company’s current price.
Separately, analysts at Citigroup Inc. downgraded shares of ChemoCentryx from a “buy” rating to a “neutral” rating in a research note to investors on Wednesday, December 4th.
ChemoCentryx (NASDAQ:CCXI) traded down 3.35% during mid-day trading on Monday, hitting $6.05. The stock had a trading volume of 596,272 shares. ChemoCentryx has a 52 week low of $4.57 and a 52 week high of $14.96. The stock has a 50-day moving average of $5.48 and a 200-day moving average of $7.92. The company’s market cap is $259.3 million.
ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.